Dual inhibition of the mTOR C1 complex and the IGF-I/IGF-IR/PI3K/Akt pathway may enhance the efficacy of mTOR inhibitors in treating AML (168–170). This evidence concerns the gene AKT1 and acute myeloid leukemia.